Protara Therapeutics Inc
$ 5.55
1.09%
26 Dec - close price
- Market Cap 297,409,000 USD
- Current Price $ 5.55
- High / Low $ 5.56 / 5.35
- Stock P/E N/A
- Book Value 3.43
- EPS -1.39
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.49 %
- 52 Week High 7.82
- 52 Week Low 2.77
About
Protara Therapeutics, Inc. (TARA) is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to developing innovative therapies for cancer and rare diseases. The company employs advanced drug delivery technologies to improve therapeutic outcomes for patients with significant unmet medical needs. With a promising pipeline of treatments and strategic collaborations, Protara is well-positioned to make a meaningful impact in the healthcare landscape, creating substantial value for its shareholders in the process.
Analyst Target Price
$25.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-11 | 2025-04-30 | 2025-03-11 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-03-13 | 2023-11-03 | 2023-08-03 | 2023-05-04 | 2023-03-08 |
| Reported EPS | -0.31 | -0.35 | -0.29 | -0.43 | -0.5024 | -0.45 | -0.97 | -0.9 | -0.87 | -1 | -0.8 | -1.55 |
| Estimated EPS | -0.3775 | -0.4 | -0.4775 | -0.565 | -0.52 | -0.8 | -0.92 | -0.92 | -0.98 | -0.87 | -0.88 | -0.75 |
| Surprise | 0.0675 | 0.05 | 0.1875 | 0.135 | 0.0176 | 0.35 | -0.05 | 0.02 | 0.11 | -0.13 | 0.08 | -0.8 |
| Surprise Percentage | 17.8808% | 12.5% | 39.267% | 23.8938% | 3.3846% | 43.75% | -5.4348% | 2.1739% | 11.2245% | -14.9425% | 9.0909% | -106.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARA
2025-12-25 00:09:14
Protara Therapeutics (Nasdaq: TARA) will host a conference call and live webcast on December 3, 2025, to present new interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The company will also provide an update on FDA feedback regarding a registrational path for TARA-002 in this patient population. The data will be featured at the 26th Annual Meeting of the Society of Urologic Oncology.
2025-12-22 20:08:57
Protara Therapeutics, Inc. (NASDAQ:TARA) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month target price of $19.50. Institutional investors, including firms like Acorn Capital and Velan Capital, have increased their holdings, now owning about 38.13% of the company's stock. Protara Therapeutics is a clinical-stage immunotherapy company focusing on HPV-driven cancers, with its lead candidate PTX-35.
2025-12-18 19:09:41
Protara Therapeutics has successfully raised $86.3 million through a public offering of its common stock. This financial move aims to bolster the company's capital, likely to fund ongoing research, development, and operational expenses within the biotech sector.
2025-12-16 17:09:15
Protara Therapeutics has successfully raised $86.3 million through a recent offering. This capital infusion is expected to support the company's ongoing operations and development initiatives.
2025-12-15 23:09:15
Protara Therapeutics successfully raised $86.3 million through a public stock offering on December 8, 2025, selling 13,043,479 shares at $5.75 each. These funds will primarily support the clinical development of TARA-002 and other corporate initiatives. Despite an analyst Buy rating with a $26.00 price target, TipRanks’ AI Analyst, Spark, rates TARA as Underperform due to the inherent risks of early-stage biotech companies, emphasizing the company's lack of revenue and persistent cash outflows, though acknowledging strong equity, low debt, and promising trial results.
2025-12-13 08:08:26
Acorn Capital Advisors LLC has significantly increased its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 36.9%, purchasing an additional 472,315 shares. This acquisition makes Protara Therapeutics the 11th biggest position in Acorn Capital Advisors' portfolio, representing approximately 3.5% of its total investments. Other institutional investors have also adjusted their holdings in TARA, and the company's stock has faced a recent 5.2% decline, though it beat analyst EPS estimates in its last quarterly report.
